New virus-based therapy targets hard-to-treat digestive cancers
NCT ID NCT06380309
First seen Jan 11, 2026 · Last updated Jun 17, 2026 · Updated 18 times
Summary
This early-stage study tests an experimental treatment called IDOV-SAFE in people with advanced digestive system cancers (like colon, rectal, stomach, or liver cancer) that have not responded to standard treatments. The study has three parts: first, finding a safe dose; second, testing safety when combined with other immune therapies; and third, measuring how well the treatment shrinks tumors. About 89 participants will be enrolled, and the main goals are to check for side effects and see if tumors respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.